HUP9700661A2 - Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására - Google Patents
Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállításáraInfo
- Publication number
- HUP9700661A2 HUP9700661A2 HU9700661A HUP9700661A HUP9700661A2 HU P9700661 A2 HUP9700661 A2 HU P9700661A2 HU 9700661 A HU9700661 A HU 9700661A HU P9700661 A HUP9700661 A HU P9700661A HU P9700661 A2 HUP9700661 A2 HU P9700661A2
- Authority
- HU
- Hungary
- Prior art keywords
- production
- profilacting
- pharmaceuticals
- alpha
- treating cancer
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 title 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001389 doxazosin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Eljárás emlősök rákős betegségeinek kezelésére vagy megelőzésérealkalmas gyógyszerkészítmény előállítására, mely hatásős mennyiségűa1-adrenőreceptőr antagőnistát vagy gyógyászati szempőntbólalkalmazható savaddíciós sóját tartalmaz. Előnyös vegyületek aprazősin, a dőxazősin és ennek 5'- és 7'-hidrőxi metabőlitjai. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1422896P | 1996-03-27 | 1996-03-27 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU9700661D0 HU9700661D0 (en) | 1997-05-28 |
HUP9700661A2 true HUP9700661A2 (hu) | 1998-11-30 |
HUP9700661A3 HUP9700661A3 (en) | 1999-06-28 |
Family
ID=21764236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9700661A HUP9700661A3 (en) | 1996-03-27 | 1997-03-26 | Use of alpha-1-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating cancer |
Country Status (16)
Country | Link |
---|---|
US (1) | US5935962A (hu) |
EP (1) | EP0799618B1 (hu) |
JP (1) | JPH10101579A (hu) |
KR (1) | KR970064607A (hu) |
AT (1) | ATE294582T1 (hu) |
AU (1) | AU733146B2 (hu) |
CA (1) | CA2201089A1 (hu) |
DE (1) | DE69733169T2 (hu) |
DK (1) | DK0799618T3 (hu) |
ES (1) | ES2242207T3 (hu) |
HU (1) | HUP9700661A3 (hu) |
IL (2) | IL120303A0 (hu) |
MY (1) | MY126321A (hu) |
NZ (1) | NZ314488A (hu) |
TW (1) | TW504386B (hu) |
ZA (1) | ZA972601B (hu) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU769446C (en) * | 1999-01-27 | 2007-09-20 | France Telecom | Method for proving the authenticity or integrity of a message by means of a public exponent equal to the power of two |
AU2001285232A1 (en) * | 2000-08-24 | 2002-03-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
PT1293198E (pt) * | 2001-09-14 | 2005-06-30 | Kissei Pharmaceutical Co Lda | Dispositivo de administracao transdermica para o tratamento de patologias do tracto urinario |
WO2006052409A2 (en) * | 2004-10-23 | 2006-05-18 | Case Western Reserve University | Peptide and small molecule agonists of epha and their uses |
US20090062326A1 (en) * | 2006-03-17 | 2009-03-05 | Spindel Eliot R | M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors |
WO2009131196A1 (ja) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | 置換ピロリジン誘導体およびその用途 |
CN104288768A (zh) | 2010-06-30 | 2015-01-21 | 盖尔德马研究及发展公司 | α2-肾上腺素能受体激动剂的用途 |
US9554988B2 (en) | 2010-06-30 | 2017-01-31 | Galderma Research & Development | Method for preventing or treating skin tumor |
US20120178757A1 (en) * | 2010-12-09 | 2012-07-12 | Nottingham University Hospitals Nhs Trust | Method For The Prevention Of Cancer Metastasis |
GR20200100456A (el) * | 2020-08-03 | 2022-03-09 | Inderes Ltd, | Συνδυασμος φαρμακων και χρηση του στη θεραπεια του καρκινου |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
US4758569A (en) * | 1987-08-26 | 1988-07-19 | Pfizer Inc. | Doxazosin as an anti-atherosclerosis agent |
ATE187069T1 (de) * | 1992-04-01 | 1999-12-15 | Pfizer | Hydroxylierte metaboliten und derivate von doxazosin gegen atherosklerose |
FR2694495B1 (fr) * | 1992-08-05 | 1994-09-23 | Synthelabo | Préparation pharmaceutique transdermique contenant de l'alfuzosine. |
US5578611A (en) * | 1992-11-13 | 1996-11-26 | Synaptic Pharmaceutical Corporation | Use of α-1C specific compounds to treat benign prostatic hyperplasia |
US5503843A (en) * | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
-
1997
- 1997-02-24 IL IL12030397A patent/IL120303A0/xx unknown
- 1997-03-20 IL IL12049597A patent/IL120495A/en not_active IP Right Cessation
- 1997-03-24 EP EP97301984A patent/EP0799618B1/en not_active Expired - Lifetime
- 1997-03-24 DE DE69733169T patent/DE69733169T2/de not_active Expired - Fee Related
- 1997-03-24 DK DK97301984T patent/DK0799618T3/da active
- 1997-03-24 ES ES97301984T patent/ES2242207T3/es not_active Expired - Lifetime
- 1997-03-24 AT AT97301984T patent/ATE294582T1/de not_active IP Right Cessation
- 1997-03-26 NZ NZ314488A patent/NZ314488A/xx unknown
- 1997-03-26 MY MYPI97001296A patent/MY126321A/en unknown
- 1997-03-26 AU AU16569/97A patent/AU733146B2/en not_active Ceased
- 1997-03-26 HU HU9700661A patent/HUP9700661A3/hu unknown
- 1997-03-26 CA CA002201089A patent/CA2201089A1/en not_active Abandoned
- 1997-03-26 ZA ZA972601A patent/ZA972601B/xx unknown
- 1997-03-26 KR KR1019970010501A patent/KR970064607A/ko not_active Application Discontinuation
- 1997-03-27 US US08/827,137 patent/US5935962A/en not_active Expired - Fee Related
- 1997-03-27 JP JP9075809A patent/JPH10101579A/ja active Pending
- 1997-07-12 TW TW086110044A patent/TW504386B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HU9700661D0 (en) | 1997-05-28 |
MY126321A (en) | 2006-09-29 |
KR970064607A (ko) | 1997-10-13 |
IL120495A0 (en) | 1997-07-13 |
ATE294582T1 (de) | 2005-05-15 |
AU1656997A (en) | 1997-10-02 |
TW504386B (en) | 2002-10-01 |
ES2242207T3 (es) | 2005-11-01 |
IL120495A (en) | 2004-09-27 |
IL120303A0 (en) | 1997-06-10 |
AU733146B2 (en) | 2001-05-10 |
EP0799618B1 (en) | 2005-05-04 |
EP0799618A3 (en) | 1997-11-12 |
DE69733169T2 (de) | 2006-01-19 |
US5935962A (en) | 1999-08-10 |
HUP9700661A3 (en) | 1999-06-28 |
NZ314488A (en) | 2000-09-29 |
EP0799618A2 (en) | 1997-10-08 |
ZA972601B (en) | 1998-09-28 |
DK0799618T3 (da) | 2005-05-30 |
DE69733169D1 (de) | 2005-06-09 |
CA2201089A1 (en) | 1997-09-27 |
JPH10101579A (ja) | 1998-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG101118A (en) | Therapeutical compounds | |
MY125821A (en) | Pharmaceutical composition of topiramate | |
BR9714363A (pt) | Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas | |
HUP9700603A1 (hu) | Gyógyászati készítmény véralvadási zavarok kezelésére | |
HUP9903694A2 (hu) | Rho kináz gátlót tartalmazó gyógyszerkészítmény | |
CY1112260T1 (el) | Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης | |
BR9709915A (pt) | Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto | |
BR9610480A (pt) | Inibição do fator alfa de necrose tumoral | |
ITRM920412A1 (it) | Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico. | |
EA200100154A1 (ru) | Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
EA200300544A1 (ru) | Эффективные противоопухолевые лекарственные средства | |
DE69426334D1 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
BR0114344A (pt) | Retinóides para o tratamento de enfisema | |
IT9048261A0 (it) | Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione. | |
HUP9700660A2 (hu) | Alfa1-adrenoreceptor antagonisták felhasználása a prosztata jóindulatú hyperpláziájának megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására | |
DK0998287T3 (da) | Anvendelse af levobupivacain | |
EE9900162A (et) | Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine | |
HUP9700661A2 (hu) | Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására | |
HUP9900819A1 (hu) | Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában | |
HUP9700806A2 (hu) | Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására | |
NO983177L (no) | Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft | |
DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
FR2725990B1 (fr) | Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux | |
AU655958B2 (en) | Use of quisqualate-receptor antagonists for treating Parkinson's disease |